Business
Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update
Clarified path to potential launch YUTREPIA upon resolution of litigation in late-2023 to mid-2024 Fortified financial position through 2024 Company to host
About this update from Liquidia Corporation
[{"type":"text","content":"Clarified path to potential launch YUTREPIA upon resolution of litigation in late-2023 to mid-2024 Fortified financial position through 2024 Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the full year ended December 31, 2022. The Company will host a webcast at 8:30 a.m. ET to discuss the 2022 financial results and provide a corporate update. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “We made notable strides toward unlocking the full potential of Liquidia in 2022. Our legal and patent wins were major achievements, clarifying the path to legal resolution. If approved, YUTREPIA will provide patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD) with the option to receive a differentiated inhaled treprostinil product via a low-resistance dry powder inhaler. The ongoing open-label extension study continues to demonstrate the merits of YUTREPIA’s dosing flexibility and durability by attaining dosing levels that have not been achievable historically with Tyvaso®, thus enhancing the clinical ability to manage patients over time. Our revenue interest financing with HealthCare Royalty, one of the marquee royalty firms, provided significant non-dilutive capital to advance our platform goals. As an example, our recently announced partnership with Mainbridge Health Partners will advance a new subcutaneous infusion pump for Treprostinil Injection, a therapeutically equivalent and less expensive generic option. We look forward to continuing to unlock value in 2023.” Corporate Updates New leadership to prepare for commercialization. During the year, the Company hired key employees in the C-suite, in the sales force and in operational units to support the potential launch of YUTREPIA. The net impact added decades of combined experience in the development and commercialization of medicines to treat pulmonary hypertension between Chief Executive Officer Dr. Roger Jeffs, Chief Medical Officer Dr. Rajeev Saggar, Head of Sales Matt Snow, and Head of Medical Affairs Gareth Gwyn. Additionally, the Company established key commercial support functions to address all stakeholders and bolstered manufacturing teams to build com...